SecSonar.com

Prelude Therapeutics Incorporated (PRLD)

Prelude Therapeutics Incorporated at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Prelude Therapeutics Incorporated (PRLD) is a Biotechnology company based in US with a market capitalization of $218.6M. Free cash flow was negative at -$56.4M. This page tracks PRLD's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 131 employees · IPO Sep 25, 2020

Valuation

Valuation & price

$4.48 · as of May 17, 2026 · -18.8% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

3.19

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$5.52$3.15$0.78Jul 25Dec 25Jul 26Jul 7, 25$0.81Jul 9, 25$0.87Jul 11, 25$0.81Jul 15, 25$0.81Jul 17, 25$0.82Jul 21, 25$0.84Jul 23, 25$0.91Jul 25, 25$0.93Jul 29, 25$0.83Jul 31, 25$0.78Aug 4, 25$0.85Aug 6, 25$0.85Aug 11, 25$0.83Aug 13, 25$0.91Aug 15, 25$0.87Aug 19, 25$0.89Aug 21, 25$1.10Aug 25, 25$1.27Aug 27, 25$1.28Aug 29, 25$1.21Sep 3, 25$1.22Sep 5, 25$1.23Sep 9, 25$1.19Sep 11, 25$1.21Sep 16, 25$1.16Sep 18, 25$1.01Sep 22, 25$1.01Sep 24, 25$1.17Sep 26, 25$1.50Sep 30, 25$1.44Oct 2, 25$1.44Oct 6, 25$1.46Oct 8, 25$1.42Oct 10, 25$1.26Oct 14, 25$1.30Oct 16, 25$1.31Oct 21, 25$1.64Oct 23, 25$1.50Oct 27, 25$1.71Oct 29, 25$1.58Oct 31, 25$1.59Nov 4, 25$1.76Nov 6, 25$1.35Nov 10, 25$1.26Nov 12, 25$1.47Nov 14, 25$1.52Nov 18, 25$1.68Nov 20, 25$1.60Nov 25, 25$1.59Nov 28, 25$1.68Dec 2, 25$1.35Dec 4, 25$1.54Dec 8, 25$1.46Dec 10, 25$1.65Dec 12, 25$1.71Dec 16, 25$1.99Dec 18, 25$1.92Dec 22, 25$2.26Dec 24, 25$2.23Dec 29, 25$2.94Jan 2, 26$2.73Jan 6, 26$2.56Jan 8, 26$2.76Jan 12, 26$2.20Jan 14, 26$2.26Jan 16, 26$1.81Jan 21, 26$1.82Jan 23, 26$2.02Jan 27, 26$2.12Jan 29, 26$1.90Feb 2, 26$2.03Feb 4, 26$2.30Feb 9, 26$2.15Feb 11, 26$2.09Feb 13, 26$2.23Feb 18, 26$2.15Feb 20, 26$2.78Feb 24, 26$2.86Feb 26, 26$2.87Mar 2, 26$2.71Mar 4, 26$2.81Mar 6, 26$3.23Mar 10, 26$3.60Mar 12, 26$3.37Mar 17, 26$3.43Mar 19, 26$3.19Mar 23, 26$3.16Mar 25, 26$3.26Mar 27, 26$3.05Mar 31, 26$3.42Apr 2, 26$3.46Apr 7, 26$4.40Apr 9, 26$4.40Apr 13, 26$4.37Apr 15, 26$5.52Apr 17, 26$4.44Apr 22, 26$4.31Apr 24, 26$4.70Apr 28, 26$4.39Apr 30, 26$5.23May 4, 26$4.74May 6, 26$4.84May 8, 26$4.86May 12, 26$4.64May 14, 26$4.47May 18, 26$4.34May 20, 26$4.50May 22, 26$4.27May 28, 26$3.93Jun 1, 26$3.82Jun 3, 26$3.66Jun 5, 26$3.81Jun 9, 26$3.94Jun 11, 26$4.11Jun 15, 26$4.46Jun 17, 26$4.35Jun 22, 26$4.32Jun 24, 26$4.27Jun 26, 26$4.38Jul 2, 26$4.93
$0.7852-week range$5.52
Loading valuation history…

Fundamentals

Key fundamentals

$218.6M

Market cap

—

Revenue growth (YoY)

85.9%

Gross margin

-$56.4M

Free cash flow (USD)

-$85.4M

Net debt

Net cash position

1.5%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2018 → 2025

FY 2018$0.00FY 2019$0.00FY 2020$0.00FY 2021$0.00FY 2022$0.00FY 2023$0.00FY 2024$7.0MFY 2025$12.1M
$0$12.1M

Free cash flow by year

2018 → 2025

FY 2018$-13.5MFY 2019$-26.4MFY 2020$-46.8MFY 2021$-85.9MFY 2022$-86.7MFY 2023$-110.6MFY 2024$-103.7MFY 2025$-56.4M
-$13.5M-$56.4M

Gross margin by year

2024 → 2025

FY 2024100.0%FY 202585.9%
100.0%85.9%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

2

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 12, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventAnnual Meeting ResultsJun 10, 2026Filing
  • 8-K eventFinancial Results and UpdateMay 12, 2026Filing
  • Quarterly report10-Q FiledMay 12, 2026Filing
  • Insider buyInsider Buy $12.5MORBIMED ADVISORS LLC · Director, 10% Owner · $12.5MApr 23, 2026Filing
  • Insider buyInsider Buy $12.5MBonita David P · Director, 10% Owner · $12.5MApr 23, 2026Filing
  • 8-K eventStock OfferingApr 21, 2026Filing
  • 8-K eventCorporate PresentationApr 20, 2026Filing
  • 8-K eventChief Medical Officer AppointmentApr 15, 2026Filing

Questions

Frequently asked questions

What is Prelude Therapeutics Incorporated's market cap?

Prelude Therapeutics Incorporated (PRLD) has a market capitalization of $218.6M.

What is PRLD's P/E ratio?

A meaningful P/E ratio is not available for PRLD — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is PRLD's price-to-book (P/B) ratio?

PRLD trades at 3.19 times book value per share.

Are insiders buying PRLD stock?

Yes — SEC Form 4 filings show 2 open-market insider buys and 0 sells at Prelude Therapeutics Incorporated in the last 90 days.

Same arena

Related companies in Biotechnology

HUMA

Humacyte, Inc.

$222.6M

YDES

YD Bio Limited Ordinary Shares

$223.1M

NBP

NovaBridge Biosciences

$213.2M

RNAC

Cartesian Therapeutics, Inc.

$212.4M

SLGL

Sol-Gel Technologies Ltd.

$225.3M

ARCT

Arcturus Therapeutics Holdings Inc.

$225.4M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.